European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
01 2019
Historique:
received: 26 07 2018
revised: 18 09 2018
accepted: 20 09 2018
pubmed: 25 11 2018
medline: 6 5 2020
entrez: 25 11 2018
Statut: ppublish

Résumé

European Breast Cancer Council manifesto and supporting article on genetic risk prediction testing in breast cancer, presented at the 11th European Breast Cancer Conference in Barcelona, Spain.

Identifiants

pubmed: 30471647
pii: S0959-8049(18)31389-3
doi: 10.1016/j.ejca.2018.09.019
pii:
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0
Biomarkers, Tumor 0

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-53

Subventions

Organisme : Cancer Research UK
ID : 10119
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 10124
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0707-10031
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-1214-20016
Pays : United Kingdom

Informations de copyright

Copyright © 2018. Published by Elsevier Ltd.

Auteurs

Emiel Rutgers (E)

Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Judith Balmana (J)

Medical Oncology Department, University Hospital Vall D'Hebron, Barcelona, Spain.

Marc Beishon (M)

European School of Oncology, Milan, Italy. Electronic address: marcbeishon@icloud.com.

Karen Benn (K)

Europa Donna - The European Breast Cancer Coalition, Milan, Italy.

D Gareth Evans (DG)

Department of Genomic Medicine, Division of Evolution and Genomic Science, University of Manchester, St Mary's Hospital, Manchester, United Kingdom.

Robert Mansel (R)

School of Medicine, Cardiff University, Cardiff, United Kingdom.

Paul Pharoah (P)

Department of Oncology, Cambridge, United Kingdom; Department of Public Health and Primary Care, Strangeways Research Laboratory, Cambridge, United Kingdom.

Victoria Perry Skinner (V)

Department of Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, the Netherlands.

Dominique Stoppa-Lyonnet (D)

Department of Genetics, Institut Curie, Paris, France; University Paris Descartes, Paris, France.

Luzia Travado (L)

Psycho-Oncology, Champalimaud Clinical Center, Lisbon, Portugal.

Lynda Wyld (L)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom; Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH